about
The multifaceted functions of CXCL10 in cardiovascular diseaseGalectin-2 induces a proinflammatory, anti-arteriogenic phenotype in monocytes and macrophagesLiposomal prednisolone inhibits vascular inflammation and enhances venous outward remodeling in a murine arteriovenous fistula model.Urokinase-receptor/integrin complexes are functionally involved in adhesion and progression of human breast cancer in vivoSimultaneous detection of NOS-3 protein expression and nitric oxide production using a flow cytometer.Variations in surgical procedures for hind limb ischaemia mouse models result in differences in collateral formation.T-cell-pre-stimulated monocytes promote neovascularisation in a murine hind limb ischaemia model.A limited role for regulatory T cells in post-ischemic neovascularizationEpigenetic control of CCR5 transcript levels in immune cells and modulation by small molecules inhibitorsMolecular imaging of bone marrow mononuclear cell survival and homing in murine peripheral artery disease.A small molecule approach to engineering vascularized tissue.Protease-activated receptor (PAR)2, but not PAR1, is involved in collateral formation and anti-inflammatory monocyte polarization in a mouse hind limb ischemia model.Short hairpin RNA gene silencing of prolyl hydroxylase-2 with a minicircle vector improves neovascularization of hindlimb ischemia.Replication-deficient human adenovirus type 35 vectors for gene transfer and vaccination: efficient human cell infection and bypass of preexisting adenovirus immunityTLR4 accessory molecule RP105 (CD180) regulates monocyte-driven arteriogenesis in a murine hind limb ischemia model.Inhibition of 14q32 MicroRNAs miR-329, miR-487b, miR-494, and miR-495 increases neovascularization and blood flow recovery after ischemia.Circulating MicroRNAs Characterizing Patients with Insufficient Coronary Collateral Artery FunctionCXCL1 microspheres: a novel tool to stimulate arteriogenesis.The isoenzyme of glutaminyl cyclase is an important regulator of monocyte infiltration under inflammatory conditions.Drug-eluting stents: results, promises and problems.Vascular growth in ischemic limbs: a review of mechanisms and possible therapeutic stimulation.Epigenetic histone acetylation modifiers in vascular remodelling: new targets for therapy in cardiovascular disease.Novel replication-incompetent vector derived from adenovirus type 11 (Ad11) for vaccination and gene therapy: low seroprevalence and non-cross-reactivity with Ad5.Increased infiltration of Chlamydophila pneumoniae in the vessel wall of human veins after perfusion.Clinical applications of the urokinase receptor (uPAR) for cancer patients.Clinical performance of drug-eluting stents with biodegradable polymeric coating: a meta-analysis and systematic review.Future potential biomarkers for postinterventional restenosis and accelerated atherosclerosis.The role of mast cells in atherosclerosis.Inhibition of Mef2a Enhances Neovascularization via Post-transcriptional Regulation of 14q32 MicroRNAs miR-329 and miR-494.Involvement of aspartic and glutamic residues in kringle-2 of tissue-type plasminogen activator in lysine binding, fibrin binding and stimulation of activity as revealed by chemical modification and oligonucleotide-directed mutagenesis.TR3 nuclear orphan receptor prevents cyclic stretch-induced proliferation of venous smooth muscle cells.The multifactorial nature of microRNAs in vascular remodelling.Vein graft failure: from pathophysiology to clinical outcomes.Plaque angiogenesis and its relation to inflammation and atherosclerotic plaque destabilization.CCR7-CCL19/CCL21 Axis is Essential for Effective Arteriogenesis in a Murine Model of Hindlimb Ischemia.Critical role of tissue kallikrein in vessel formation and maturation: implications for therapeutic revascularization.Plaque angiogenesis and intraplaque hemorrhage in atherosclerosis.Treatment with intramuscular vascular endothelial growth factor gene compared with placebo for patients with diabetes mellitus and critical limb ischemia: a double-blind randomized trial.A novel urokinase receptor-targeted inhibitor for plasmin and matrix metalloproteinases suppresses vein graft disease.Lysophosphatidic acid triggers mast cell-driven atherosclerotic plaque destabilization by increasing vascular inflammation.
P50
Q27010051-8B48F07D-72E2-41DE-9098-CDF404007DD9Q27309121-51280338-C635-427E-8208-46EC12BFE806Q27322891-761318A9-F5B1-4F75-A57C-C00611ABBBB0Q28350698-F1F7010C-A06C-4F10-946D-E043FBDD4DFFQ32122812-877BD23B-164E-489D-B2BA-F14D03E0CF65Q33655842-1222924B-18A0-46BA-B482-8213A8606BFFQ33782488-C7B468F7-46E6-49B0-98AE-C0237EF4DC15Q33852551-96114247-1D9F-431F-BFD9-A6C459C7ED57Q34066178-D4F8F296-07EB-4429-8090-8FD2DE52A0BAQ34125754-5D95E545-2599-47F8-8AEE-CF7EA0120263Q34569984-AA1EBAE6-BD1E-4F6E-AFDB-282A3C166506Q34700750-1578A284-6D47-487D-8A6E-5DBBD1A73F82Q35007366-9B1D2308-93B1-486C-B669-C302FDC1ECBCQ35155049-7ABAEE81-325E-4743-BD9E-EF7F1417FE71Q35191061-414B227F-0CD1-4641-9228-899DAF79493AQ35217673-2FC11242-E93D-4A5F-A495-13BF762CD61CQ35761959-F30F80E5-A3C6-4084-9D71-442903EBC7CAQ35864800-DD132B4C-D183-458A-9931-4A0F9F55736FQ36038807-EE40E15F-152A-4C28-976E-6A476474B297Q36049064-8958A464-1C8D-4F04-9294-A0F4E5F4632AQ37173528-73408E59-4F0C-4D79-8778-C149D821AE2BQ37369595-E2B83042-F94F-4793-B250-BCCB04A830DCQ37596543-C20C2CFD-BBEC-4A74-82B3-AD92A468AD6AQ37857441-BBA4D050-D489-40AC-AD1E-80F24BE82A27Q37895301-E742CA49-D73B-4A7D-B9D3-A1C03079AF9FQ37901970-0D667E6D-17B7-4468-A98F-DBE51296DF0BQ37980498-1B3242BF-AB0D-4BAD-8192-D584B07C8176Q38265832-B1652F54-0E54-4047-8E9D-62F73EBE635FQ38287926-3D96457D-A9C3-4D98-B319-18CCFCB100F0Q38338138-AAD83A75-E35E-4E67-8E1F-90B5F4CB938AQ38623534-6DC30BBA-E0E7-4B9E-B9D2-29A461109809Q38749173-E16FA351-7B94-40AC-9C8B-B56464BE0DA1Q38837879-59D004C7-8686-46F9-BBD3-E34B6BFFCC2EQ38912461-2E683C69-2DA2-4AF1-95DB-974185DD0D73Q38919738-D01C2E21-7FF5-4C53-B66B-A460DA0C047DQ39248182-CF6D690E-5592-42AF-A8E2-99C9C60FB260Q39257536-B9E1140E-248F-4860-AD0F-784B42239EAAQ39349848-939754AA-40D2-4D45-8ADF-221A87D3BF94Q39690874-FD2A0E3D-0DC4-4D04-80DD-0F62FB6DA2EAQ39741685-F8E5D8B2-C0F0-400A-A076-ED4439616834
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Paul Quax
@ast
Paul Quax
@en
Paul Quax
@es
Paul Quax
@nl
Paul Quax
@sl
type
label
Paul Quax
@ast
Paul Quax
@en
Paul Quax
@es
Paul Quax
@nl
Paul Quax
@sl
prefLabel
Paul Quax
@ast
Paul Quax
@en
Paul Quax
@es
Paul Quax
@nl
Paul Quax
@sl
P106
P21
P2798
P31
P496
0000-0002-6853-5760